Hi, russett -
"I have little to say here on this subject except that J&J was one of the big experimenters with DMSO in the sixties,...reflect on that and realize that DMSO mixed with a pain killer may be as effective as Pennsaid,...the Pennsaid patent cannot protect against many similar mixtures being developed and marketed."
As those who have studied the matter are aware, you are correct about JnJ's early efforts with DMSO. As you may (or may not) know there are actually two patents, the second being a CIP (Continuation-In-Part) of the first patent.
However, there is a Terminal Disclaimer on the first patent.
I've often wondered why it is that DMX is so confident that it will be able to extend the initial patent, in view of the Terminal Disclaimer. The early efforts of JnJ with DMSO, and DMX's confidence about its ability to extend the patent make me wonder: could it be because JnJ holds the disclaimer? Just a thought...
"...the Pennsaid patent cannot protect against many similar mixtures being developed and marketed..."
If you are talking about a generic prescription product, or any product that claims therapeutic benefit, then you are wrong. If you are talking about something like Blue Goo, that can be used for axle grease or be slapped on sore elbows, and has undifferentiated usage with no claims to therapeutic benefit - you are possibly right: as long a the product in question doesn't stray within the orbit of Pennsaid's patent.
Some thoughts from di7026...
stockhouse.ca
stockhouse.ca
stockhouse.ca
"You should think long and hard as to why J&J does not take out DMX right now for peanuts given what the projected market penetration and sales are for Pennsaid if they could capture 5% of the known market"
Many of us have thought long and hard about that.
stockhouse.ca
"Now they tell me that no mayor is interested enough to make an offer, and no one really knows why???
C'est la vie!"
Ce n'est pas la vie.
In fact, while RK has stated that she has had exploratory discussions with other companies, she has always stated, and continues to state, that JnJ is the preferred candidate for US distribution rights. Continuation of the Standstill Agreement would not prevent RK from discussing the matter with other companies - but she could not negotiate terms for marketing and distribution with any other company.
Given the risk inherent in Pennsaid until approvals are gained, why would any company invest that kind of money when there's a possibility (however remote) that the product won't be approved? If such a takeover were to be made (friendly or unfriendly) the logical time to do it is after approval - and we ain't there yet.
N'est-ce pas?
Regards,
Jim |
